India's Panacea Biotec begins producing Russia's Sputnik V vaccine
Panacea Biotec plans to produce 100 million doses of Sputnik V annually, Russian Direct Investment Fund said. Phial labelled "Sputnik V coronavirus disease vaccine", March 24, 2021. Reuters
Indian biotech firm Panacea Biotec Ltd on Monday began production of Russia's Sputnik V vaccine against Covid-19, said the Russian Direct Investment Fund (RDIF), which markets the shot internationally.
The first batch made by the Indian manufacturer will be shipped to Gamaleya, the Moscow institute which developed the vaccine, for quality controls, RDIF said in a statement.
Full-scale production is expected to begin this summer, RDIF added. Panacea Biotec plans to produce 100 million doses of Sputnik V annually, RDIF said in April.
29.12°C Kathmandu
.jpg&w=300&height=200)
